-
1834-A Jaclif Court
Tallahassee, FL 32308 -
(844) 4-WOUND-4
(844-496-8634) - Support@regenxwoundcare.com
Conventional medical care is often unable to heal chronic non-healing wounds (CNHW) for several reasons. Although basic wound care practices such as the application of disinfection agents and sterile dressings may be enough to resolve wounds for healthy patients, they may not be enough to resolve such problems in those with the following conditions or lifestyle behaviors:
Unfortunately, currently, we do not accept any other insurance besides MEDICARE (Part B).
Keep in mind, amniotic graft treatment is a relatively new and innovative biotechnology, and it takes time to move the wheels of progress.
If you do not have MEDICARE (Part B), we suggest you conduct an online search for providers who accept your insurance.
Amniotic tissues are obtained from the placentas of donors who have given birth.
The placenta is a structure that develops within the uterus that encases a baby within the mother’s body. This tissue is normally discarded but is now being donated as a valuable regenerative resource for human cells, tissues, and tissue-based products (HCT/Ps).
What makes human amniotic membrane (HAM) allografts so effective are their remarkable regenerative properties, especially what is known as the extracellular matrix (ECM).
The ECM is composed of a network of proteins, glycosaminoglycans (GAGs), and other molecules essential for several reasons. It provides a physical scaffold—a 3D structure—for cells to adhere to, which allows tissues to maintain their shape and integrity across organs and physiological systems. The ECM also triggers biochemical signaling pathways within the cell, controlling processes such as cellular communication, growth, and movement.
The extracellular matrix contains growth factors, collagen, enzymes, fibronectin, laminin, elastin, hyaluronic acid, and proteoglycans. Together, these healing components work synergistically to build and restore tissue like nothing else can.
There are no risks of rejection of amniotic allografts by the body. This is due to the unique structures of these tissues.
The placenta possesses “immunologically privileged” status. More specifically, amniotic tissue expresses very low levels of human leukocyte antigens (HLAs), which are the biomarkers the immune system employs to identify foreign cells. Moreover, amniotic membranes have remarkable anti-inflammatory and immunosuppressive properties that suppress the activation of T-cells, macrophages, and other immune cells, further reducing the risk of rejection.
Collectively, these unique characteristics allow a baby to thrive and grow within the mother’s womb without rejection despite being a body within a body.
During debridement (the process of removing dead, damaged, or infected tissues), there may be some discomfort, but nothing intolerable. Our medical professionals provide lidocaine to numb pain whenever it is necessary to do so.
However, in most cases, the discomfort is nearly non-existent. Moreover, many patients are already experiencing numbness due to underlying conditions such as diabetes or peripheral neuropathy (PN).
There are types of wounds we cannot treat unless certain medical interventions are taken first.
Although we can remove some infected tissue through debridement, we may not be able to treat the wound with an amniotic allograft until a course of antibiotics has successfully eliminated any remaining infection.
While debridement can remove some dead tissue, we are not equipped to address gangrene. This life-threatening condition must be treated in the hospital and be completely eliminated before we can proceed.
We do not treat cancerous ulcers and lesions. Certain other types of cancers may also be contraindicated for our amniotic allografts. If or when such cancers are subdued, we may be able to initiate treatment at that point.
Moreover, smokers may not receive treatment unless they are able to successfully implement cessation control. This is because smoking impairs the regenerative process.
How long it takes to heal your wound depends on the quality and severity of that wound. Some wounds are large and extensive, requiring the maximum length of time, up to 10 weeks. Other wounds may be smaller and shallower, requiring only three or four weeks. Most patients experience the best results after six weeks.
The quality of your nutrition, stress levels, and sleep can also influence the speed of your healing.
There’s a reason you have a chronic non-healing wound (CNHW). In addition to immobility, your regenerative capacity is impaired by certain lifestyle behaviors and/or underlying diseases. You may be taking certain medications that interfere with healing. Chronic stress, poor sleep patterns, and malnutrition also play roles.
Although human amniotic membrane (HAM) allografts possess extraordinary regenerative capabilities that can heal your wounds despite the aforementioned circumstances, it would be in your best interest to improve some of these areas if you want to accelerate results.
The success rate of amniotic membrane allografts depends on various factors such as the quality of the allografts themselves, the type of wound that is treated, the hygiene of the patient’s environment, the compliance of caregivers responsible for adjusting the patient’s position and dressing changes, and any behavioral patterns that could impact the healing process.
However, generally speaking, the scientific literature has shown that this treatment is extremely reliable with a success rate of 90-95%.
